Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Joor Yung Huh 2 Articles
Bcl-2 Expression in Endometrial Hyperplasia and Carcinoma
Jong Hyeok Kim, Chang Won Koh, Joor Yung Huh, Bong Hee Kim, Hun Sik Kong, Jun Hee Na, Yong Nam Kim, Young Tak Kim, Joo Hyun Nam
J Korean Cancer Assoc. 1998;30(6):1207-1218.
AbstractAbstract PDF
PURPOSE
To speculate the role of bcl-2 protooncogene in endometrial carcinogenesis by determination of the expression of bcl-2 in endometrial hyperplasia and carcinoma.
MATERIALS AND METHODS
We studied bcl-2 expression by an immunohistochemical method in the paraffin-embedded blocks of 78 patients with endometrial hyperplasia, 64 with simple hyperpasia, 9 with complex hyperplasia and 5 with atypical hyperplasia respectively, and 33 endometrial carcinoma treated at Asan Medical Center from June, 1989 to May, 1997. Intensity of bcl-2 staining was scored on a scale of 0 to 4, calibrated by comparison with stromal lymphocytes, which always received a score of 4.
RESULTS
The results of this study showed that bcl-2 was relatively highly expressed in simple (n= 64), complex (n=9) and atypical hyperplasias (n=5) with mean staining scores of 2.95+/-1.09 (Mean+Standard Deviation), 2.78+/-1.20 and 3.60+/-0.89 respectively, which showed no difference among histologic types. In endometrial carcinoma, the expression of bcl-2 was significantly down regulated (mean score=1.76+/-1.35) compared with that of hyperplasia, and did not conelate with FIGO surgical stage. However, grade III tumor showed significantly lower expression that grade I or II tumor.
CONCLUSION
Bcl-2 expression is down regulated in endometrial carcinoma than endo- metrial hyperplasia, and correlates with tumor grade, which suggest that bcl-2 expression might be the result of carcinogenesis or bcl-2 plays only an adjunctive role in the endometrial carcinogenesis.
  • 2,706 View
  • 52 Download
Close layer
Peripheral T - cell Lymphomas Presenting as Fever of Unknown Origin
Dae Seog Heo, Keun Seok Lee, Joor Yung Huh, Yung Jue Bang, Seon Yang Park, Chul Woo Kim, Byoung Kook Kim, Noe Kyeong Kim
J Korean Cancer Assoc. 1998;30(2):329-337.
AbstractAbstract PDF
PURPOSE
Peripheral T-cell lymphomas(PTCL) show diverse clinical and histological characteristics and should be understood as mixtures of heterogeneous entities. Although many clinical and biological parameters have been proposed for classifying PTCL into different prognostic groups, few parameters have turned out to be appropriate for classification. To investigate the clinical significance of FUO presentation in PTCL, comparisons of clinical parameters were performed using non-FUO presentation as a control.
MATERIALS AND METHODS
66 cases of Korean PTCL were divided into FUO group and non-FUO group according to the presentation and compared with each other.
RESULTS
Among 66 patients of PTCL, 19 patients presented with FUO. Compared with non-FUO group, FUO group showed no significant age and sex ratio differences. FUO group showed more advanced stage, worse performance status than non-FUO group. Predominant sites of definite diagnosis were skin, gastrointestinal tract and liver in FUO group and nasal cavity and paranasal sinus in non-FUO group. There were no significant differences between histologic classifications of both groups. Survival analysis revealed significant differences between both groups. FUO group showed significantly shorter survival. Prognostic factor analysis(multivariate) was done with stage, LDH level, performance status, and FUO status. FUO status, stage and performance status were significant determinants of survival, but LDH level proved to have no prognostic implication.
CONCLUSION
PTCL with FUO presentation showed such distinct characteristics that the authors propose fever of unknown origin(FUO) as a clinical parameter for classifying PTCL. Further studies are needed to identify biological parameters which characterize PTCL with FUO presentation.
  • 2,780 View
  • 21 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP